Medicare forced to pay for unproven devices for four years straight

What it does

This bill creates a fast-track Medicare coverage pathway for medical devices that the FDA has designated as 'breakthrough' innovations. Manufacturers can apply for a 4-year 'transitional coverage period' during which Medicare must cover their device, and the government must issue a final coverage decision before that period ends. The bill appropriates $10 million annually through 2031 to administer the program.

Why we flagged it

The bill's core function is to guarantee Medicare payment for FDA-designated breakthrough devices during a 4-year window with minimal clinical-evidence thresholds, effectively subsidizing device manufacturers' market entry at public expense. While framed as 'patient access,' the mechanism prioritizes manufacturer certainty over evidence-based coverage.

What the text implies

• The bill requires Medicare coverage based solely on FDA priority-review designation, not on clinical proof of superiority or cost-effectiveness—a lower evidentiary bar than standard Medicare coverage policy, potentially locking in payment for devices that may not outperform existing alternatives.
• The 4-year transitional period creates a guaranteed revenue stream for device manufacturers regardless of real-world clinical outcomes, shifting financial risk from industry to Medicare and taxpayers.
• The bill does not require manufacturers to conduct post-market surveillance or outcomes studies during the transitional period, meaning Medicare may pay for devices with unknown long-term safety or efficacy profiles.
• The $10M annual appropriation is modest relative to potential device-coverage costs; actual Medicare spending on breakthrough devices during the 4-year windows could far exceed this administrative budget, creating hidden fiscal exposure.

Who it affects

Patients may gain faster access to potentially beneficial new medical devices, but the bill shifts coverage risk to Medicare (and taxpayers) by requiring payment during a 4-year window with minimal clinical evidence requirements—devices need only FDA priority review, not proven superiority. The long-term cost to the program and whether patients actually benefit from devices covered under weaker evidence standards is unclear.

Who stands to gain

• medical device manufacturers (especially those with FDA priority-review designations)
• biotech and medtech companies with breakthrough-device pipelines

Named in the bill

Centers for Medicare & Medicaid Services (CMS), FDA (Food and Drug Administration), Medicare (Social Security Act Title XVIII), Regeneron Pharmaceuticals (REGN), Boston Scientific (BSX), Genpact (GNPX)

Where it stands

5 cosponsors: 3 Democrats, 2 Republicans.

• May 12, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 12, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

25 lobbying clients named this bill on 37 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $11,117,988 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Todd Young, the sponsor, reported $704,220 in PAC receipts in the 2026 cycle. $19,000 of that came from 5 PACs tied to these lobbying clients.

• Philips Holding USA Inc. — $1,950,000 on 3 filings
• Advanced Medical Technology Assn — $1,913,000 on 2 filings
• Johnson & Johnson Services Inc — $1,440,000 on 1 filing
• Boston Scientific Corporation — $1,212,000 on 2 filings
• Medtronic Inc — $1,180,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.